Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-α antagonists in management of ankylosing spondylitis: A dynamic population modelling study

Cost Effectiveness and Resource Allocation

Volumn 13, Issue 1, 2015, Pages

  Tran Duy, An ^a,b   Boonen, Annelies ^a   Van de Laar, Mart A F J ^c   Severens, Johan L ^d  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Ankylosing spondylitis; Budget impact; Cost effectiveness; Cost utility; Discrete event simulation; Health impact; Microsimulation; Modelling; Population dynamics; Tumor necrosis factor

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BUDGET; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED;

EID: 84959140852     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/s12962-015-0044-x     Document Type: Article

References (38)

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379-90.
2. Boonen A, Mau W. The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol. 2009;27:S112-7.
3. Franke LC, Ament AJHA, van de Laar MAFJ, Boonen A, Severens JL. Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol. 2009;27:S118-23.
4. Dougados M, Dijkmans B, Khan M, Maksymowych W, van der linden S, Brandt J. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis. 2002;61:iii40-50.
5. Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology. 2005;44:670-6.
6. Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sörensen H, Zeidler H, Sieper J. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis. 2008;67:340-5.
7. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Reddig J, Sieper J. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum. 2003;48:2224-33.
8. Glintborg B, Østergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis. 2010;69:2002-8.
9. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, Dougados M, Geher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Bohm H, van Royen BJ, Braun J. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2006;65:442-52.
10. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70:896-904.
11. Pham T, Fautrel B, Dernis E, Goupille P, Guillemin F, Le Loët X, Ravaud P, Claudepierre P, Miceli-Richard C, De Bandt M. Recommendations of the French Society for Rheumatology regarding TNFα antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine. 2007;74:638-46.
12. Keat A, Barkham N, Bhalla A, Gaffney K, Marzo-Ortega H, Paul S, Rogers F, Somerville M, Sturrock R, Wordsworth P. BSR guidelines for prescribing TNF-α blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology. 2005;44:939-47.
13. Reveille JD, Ximenes A, Ward MM. Economic considerations of the treatment of ankylosing spondylitis. Am J Med Sci. 2012;343:371-4.
14. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Watkins J, Trueman P. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practice-budget impact analysis. Value Health. 2007;10:336-47.
15. Drummond M, Brown R, Fendrick AM, Fullerton P, Neumann P, Taylor R, Barbieri M. Use of pharmacoeconomics information-report of the ISPOR task force on use of pharmacoeconomic/health economic information in health care decision making. Value Health. 2003;6:407-16.
16. van Velden ME, Severens JL, Novak A. Economic evaluations of healthcare programmes and decision making: the influence of economic evaluations on different healthcare decision-making levels. Pharmacoeconomics. 2005;23:1075-82.
17. Eddama O, Coast J. A systematic review of the use of economic evaluation in local decision-making. Health Policy. 2008;86:129-41.
18. Eddama O, Coast J. Use of economic evaluation in local health care decision-making in England: a qualitative investigation. Health Policy. 2009;89:261-70.
19. Gaujoux-Viala C, Fautrel B. Cost Effectiveness of therapeutic interventions in ankylosing spondylitis. Pharmacoeconomics. 2012;30:1145-56.
20. Tran-Duy A, Boonen A, van de Laar MAFJ, Franke AC, Severens JL. A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis. Ann Rheum Dis. 2011;70:2111-8.
21. Garrett S, Jenkinson T, Kennedy G, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286-91.
22. Calin A, Garrett S, Whitelock H, Kennedy L, O'hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281-5.
23. Spoorenberg A, Van der Heijde D, De Klerk E, Dougados M, De Vlam K, Mielants H, Van der Tempel H, Van der Linden S. A comparative study of the usefulness of the Bath Ankylosing Spondylitis Functional Index and the Dougados Functional Index in the assessment of ankylosing spondylitis. J Rheumatol. 1999;26:961-5.
24. Akkoc N, Khan MA. Overestimation of the prevalence of ankylosing spondylitis in the Berlin study: comment on the article by Braun et al. Arthritis Rheum. 2005;52:4048-9.
25. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J. Prevalence of spondylarthropathies in HLA B27 positive and negative blood donors. Arthritis Rheum. 1998;41:58-67.
26. Muñoz-Fernández S, De Miguel E, Cobo-Ibáñez T, Carmona L, Steiner M, Descalzo M, Ferreira A, Balsa A, Martín-Mola E. Early spondyloarthritis: results from the pilot registry ESPIDEP. Clin Exp Rheumatol. 2010;28:498-503.
27. Kaipiainen-Seppanen O, Aho K, Heliovaara M. Incidence and prevalence of ankylosing spondylitis in Finland. J Rheumatol. 1997;24:496-9.
28. Bakland G, Nossent HC, Gran JT. Incidence and prevalence of ankylosing spondylitis in Northern Norway. Arthritis Care Res. 2005;53:850-5.
29. CBS. Statline-Centraal Bureau voor de Statistiek. http://statline.cbs.nl/statweb/.
30. Kruithof E, Van den Bosch F, Baeten D, Herssens A, De Keyser F, Mielants H, Veys EM. Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis. 2002;61:207-12.
31. Koopmanschap MA, Rutten FF. A practical guide for calculating indirect costs of disease. Pharmacoeconomics. 1996;10:460-6.
32. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
33. R Core Team: R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. http://www.R-project.org/.
34. Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, Orlewska E, Penna P, Rodriguez Barrios J-M, Shau W-Y. Budget Impact Analysis-Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17:5-14.
35. CVZ: Richtlijnen farmaco-economisch onderzoek, geactualiseerde versie. Diemen: College voor Zorgverzekeringen; 2006.
36. Hoyle M, Anderson R. Whose costs and benefits? Why economic evaluations should simulate both prevalent and all future incident patient cohorts. Med Decis Making. 2010;30:426-37.
37. Raad voor de Volksgezondheig en Zorg: Zicht op zinnige en duurzame zorg. http://rvz.net/uploads/docs/Achtergrondstudie_-_Zicht_op_zinnige_en_duurzame_zorg.pdf.
38. Stolwijk C, Boonen A, van Tubergen A, Reveille JD. Epidemiology of spondyloarthritis. Rheum Dis Clin N Am. 2012;38:441-76.